维亚臻生物技术(上海)有限公司
20-99人
公司优势
Visirna was founded in 2022 and has established a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR), a leading global company in small RNA drug development. The company currently has three clinical-stage siRNA drugs targeting cardiovascular and metabolic diseases. In addition, the company possesses independent R&D capabilities and is exploring liver-specific and extrahepatic delivery technologies, as well as broader therapeutic areas.
The company's current pipeline is at the forefront of its competitors, with targets supported by clear genomic and biological evidence, utilizing Arrowhead's validated delivery and chemical modification technology platforms. The company adopts a China-US collaborative clinical development and registration strategy to accelerate product commercialization.
The company's internal R&D capabilities will further enrich the clinical development pipeline in cardiovascular and metabolic diseases, promoting long-term sustainable development, while forming an integrated industry chain from R&D, production to sales through internal and external resources.
Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR). Based in China, with a global vision, Visirna aims to be a leading player in the research and development of oligonucleotide therapeutics. We currently have three first-in-class late clinical-stage siRNA candidates licensed from Arrowhead Pharmaceuticals for the treatment of cardiovascular and metabolic diseases.
We are rapidly advancing our clinical pipelines in an array of trials. Currently we have one ongoing Phase 3 registration trial in FCS in China, and will soon join multiple MRCT trials for cardiovascular diseases. At the same time, we are also conducting a phase 2 PoC (proof of concept) trial in NASH.
Visirna is setting up a 1500 sqm R&D lab in Suzhou BioBAY to strengthen our existing clinical portfolio for cardiovascular and metabolic diseases. Our goal is to develop a comprehensive treatment repertoire that can effectively address the complex nature of these diseases and provide better outcomes for patients.
The company's current pipeline is at the forefront of its competitors, with targets supported by clear genomic and biological evidence, utilizing Arrowhead's validated delivery and chemical modification technology platforms. The company adopts a China-US collaborative clinical development and registration strategy to accelerate product commercialization.
The company's internal R&D capabilities will further enrich the clinical development pipeline in cardiovascular and metabolic diseases, promoting long-term sustainable development, while forming an integrated industry chain from R&D, production to sales through internal and external resources.
Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR). Based in China, with a global vision, Visirna aims to be a leading player in the research and development of oligonucleotide therapeutics. We currently have three first-in-class late clinical-stage siRNA candidates licensed from Arrowhead Pharmaceuticals for the treatment of cardiovascular and metabolic diseases.
We are rapidly advancing our clinical pipelines in an array of trials. Currently we have one ongoing Phase 3 registration trial in FCS in China, and will soon join multiple MRCT trials for cardiovascular diseases. At the same time, we are also conducting a phase 2 PoC (proof of concept) trial in NASH.
Visirna is setting up a 1500 sqm R&D lab in Suzhou BioBAY to strengthen our existing clinical portfolio for cardiovascular and metabolic diseases. Our goal is to develop a comprehensive treatment repertoire that can effectively address the complex nature of these diseases and provide better outcomes for patients.
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
负责步步高家教机及小天才电话手表的销售与宣传推广工作。
电动车电池厂家办事处，主要经营电动车电池批发，办公地点，约15天后将搬迁至下黄小学旁，位于城厢区医院附近，现址在荔城区赤溪宝龙鞋厂内。
招聘餐饮服务员
江西***兴浩汽车有限公司，员工人数不足50人，企业性质为民营企业，所属行业为汽车。
青岛泰金食品有限公司成立于2016年11月14日，位于中国（山东）自由贸易试验区青岛片区前湾保税港区汉城路3号美晶大厦二区六楼606-15（蛙声一片创客园区）（B），所属行业为批发和零售业，主要从事食品、饮料、酒水领域，员工规模为1-49人。